
    
      A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase III
      efficacy and safety study of TC-5214 (S-mecamylamine) in flexible doses as an adjunct to an
      antidepressant in patients with major depressive disorder with an inadequate response to
      antidepressant therapy.
    
  